At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
In Brief
A Phase 4 clinical trial evaluating Ixazomib, Bortezomib, and 3 other interventions for Relapsed and/or Refractory Multiple Myeloma. Completed, enrolled 45 participants across 23 sites.
Detailed Summary
The purpose of this study is to investigate the efficacy and safety of long-term administration of the oral proteasome inhibitor ixazomib as part of ixazomib in combination with lenalidomide and dexamethasone (IRd) therapy in patients with relapsed and/or refractory multiple myeloma (RRMM) treated initially with an injectable proteasome inhibitor-based therapy.
Study Details
Timeline
Interventions
Ixazomib capsules
Bortezomib injections
Carfilzomib intravenous infusions
Lenalidomide capsules
Dexamethasone tablets